ROS-responsive polyelectrolyte nanogel

chemo-ferroptosis synergy

A hyaluronan-chitosan nanogel co-delivering methotrexate and sorafenib that releases drugs in response to elevated oxidative stress in tumors, achieving synergistic chemotherapy and ferroptosis.

Cui, Xiaonan · Wu, Jin · Sun, Chunyang · Ye, Zhaoxiang

International Journal of Biological Macromolecules 2026

Specifications

Tumor growth inhibition rate

{'zh': '75.85', 'en': '75.85'} %

Advantages

Active tumor targeting

Hyaluronic acid binds to CD44 receptors on tumor cells, enabling efficient accumulation of the nanogels in tumors.

ROS-responsive release

In the tumor microenvironment with elevated oxidative stress, the nanogel network loosens to release drugs, reducing off-target toxicity.

Chemo-ferroptosis synergy

Co-delivery of methotrexate (chemotherapy) and sorafenib (ferroptosis inducer) enhances cancer cell killing.

Low systemic toxicity

Compared with free drug treatment, the nanogel formulation significantly reduces systemic toxicity.

Applications

• breast cancer therapy：Targeted combination therapy for breast cancer to improve efficacy and reduce toxicity.
• responsive drug delivery：On-demand drug release in response to tumor microenvironment ROS.
• chemo-ferroptosis combination therapy：Combining chemotherapy and ferroptosis to enhance antitumor efficacy.